Access says MuGard decreases oral mucositis by 47%

By Elaine Rigoli

Tampa, Fla., June 22 - Access Pharmaceuticals, Inc. released clinical results from a study of MuGard, an oral rinse product for the prevention and treatment of oral mucositis, the debilitating side-effect which afflicts more than 20% of cancer patients undergoing radiation and chemotherapy.

"In our clinical study of head and neck cancer patients receiving radiation therapy, 47% of patients using MuGard had no mucositis. Historically, patients on the same treatment without MuGard had a high rate of mucositis, with only 7% of patients experiencing no mucositis," chief executive officer Rosemary Mazanet said in a news release.

"In addition, the number of patients with mild to moderate mucositis was statistically reduced as well by the use of MuGard. There is currently no well-accepted treatment for mucositis, and we believe that these results demonstrate that MuGard should be a valuable supportive care option for cancer patients," she said.

The estimated size of the market for this indication in the United States exceeds $1 billion. The company said it is actively seeking marketing partners for this product.

Access said it plans to submit a 510(k) application for marketing approval in the third quarter of this year.

Access, based in Dallas, is an emerging biopharmaceutical company that develops and commercializes products for the treatment and supportive care of cancer patients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.